What is the clinical evidence from this study?

Study design: Other. Population: Heart failure and cardiac fibrosis (n=15). Intervention: [D-Ala2]GIP (DA-GIP) vs. Vehicle (0.9% normal saline). Primary outcome: Myocardial fibrosis (collagen volume fraction) and systolic function (p=<0.005).

What does this research mean for the field?

Glucose-dependent insulinotropic polypeptide (GIP) receptor agonism suppresses cardiac fibrosis and improves cardiac function in heart failure through Akt-dependent endothelial nitric oxide synthase (eNOS) activation and nitric oxide production. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate whether activating the glucose-dependent insulinotropic polypeptide (GIP) receptor suppresses cardiac fibroblast activity and mitigates heart failure, and to elucidate the underlying signaling pathways.

September 2, 2026Journal of Biomedical ScienceOpen Access

DA-GIP reduces myocardial fibrosis and systolic dysfunction in heart failure rats via Akt-dependent nitric oxide signaling.

Q: What are the key findings of this study?

DA-GIP significantly reduced myocardial fibrosis, chamber dilatation, and systolic dysfunction in rats with experimental heart failure through Akt-dependent nitric oxide signaling.

Q: What does this research mean for the field?

Glucose-dependent insulinotropic polypeptide (GIP) receptor agonism suppresses cardiac fibrosis and improves cardiac function in heart failure through Akt-dependent endothelial nitric oxide synthase (eNOS) activation and nitric oxide production. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To investigate whether activating the glucose-dependent insulinotropic polypeptide (GIP) receptor suppresses cardiac fibroblast activity and mitigates heart failure, and to elucidate the underlying signaling pathways.

View Full Paper

Ask AI

Bookmark

Why the study?

How GIP receptor activation regulates cardiac fibrogenesis and modulates cardiac function in heart failure remained unclear.

Population

Human cardiac fibroblasts and rats with isoproterenol-induced heart failure

Comparison

DA-GIP administration vs untreated controls

Design

In vitro cellular and in vivo animal experimental study

Follow-up

24 h for fibroblasts and 2 weeks for rats

Key result

DA-GIP significantly reduced myocardial fibrosis, chamber dilatation, and systolic dysfunction in rats with experimental heart failure through Akt-dependent nitric oxide signaling.

Authors

TLTing‐Wei Lee TLTing-I Lee SHSatoshi Higa

Discussion

Member takes

Overview

Hypothesis-generating for GIP agonism in HF remodeling; human trials required before clinical consideration.

Key Points

To investigate whether activating the glucose-dependent insulinotropic polypeptide (GIP) receptor suppresses cardiac fibroblast activity and mitigates heart failure, and to elucidate the underlying signaling pathways.
Treated human cardiac fibroblasts with [D-Ala2]GIP (DA-GIP; 10, 100, or 300 nM) for 24 hours to analyze cell migration, collagen synthesis, and intracellular signaling pathways.
Administered DA-GIP (24 nM/kg twice daily for 2 weeks) to rats with isoproterenol-induced heart failure to assess cardiac remodeling, chamber dimensions, and systolic function using echocardiography and Masson's trichrome staining.
DA-GIP (300 nM) significantly decreased cardiac fibroblast migration and suppressed the expression of pro-collagen IA1, pro-collagen III, and TGF-β1 proteins.
DA-GIP enhanced Akt and eNOS activation to stimulate nitric oxide production; pharmacologic inhibition of Akt blocked eNOS activation, and L-NAME attenuated DA-GIP antifibrotic effects.
In heart failure rats, DA-GIP treatment reduced myocardial fibrosis, attenuated ventricular chamber dilatation, and improved systolic dysfunction.

Structured PICO

Population

15 male Wistar rats, including 10 with isoproterenol-induced heart failure, treated with DA-GIP or vehicle for 2 weeks, alongside in vitro human cardiac fibroblast experiments.

Intervention

[D-Ala 2 ]GIP (DA-GIP; 10, 100, or 300 nM for 24 h in cells; 24 nM/kg twice daily for 2 weeks in rats)

Comparator

Untreated (control) cells and heart failure rats without DA-GIP administration

Outcome

Fibroblast migration, collagen production, intracellular signaling, cardiac structure, function, and fibrosissurrogate

Main Result

p-value: p=<0.005

GIP receptor agonism suppresses cardiac fibroblast activity and improves cardiac remodeling and function in experimental heart failure via Akt-dependent NO signaling.

Limitations

The results were obtained from cellular and animal models, and their clinical applicability remains to be established.
Future studies should incorporate pressure-volume loop analysis to further clarify the effects of GIP receptor agonism on ventricular mechanics in heart failure.

Cite This Study

Lee et al. (2026) studied Heart failure and cardiac fibrosis (n=15). [D-Ala2]GIP (DA-GIP) vs. Vehicle (0.9% normal saline) was evaluated on Myocardial fibrosis (collagen volume fraction) and systolic function (p=<0.005). DA-GIP significantly reduced myocardial fibrosis, chamber dilatation, and systolic dysfunction in rats with experimental heart failure through Akt-dependent nitric oxide signaling.

synapsesocial.com/papers/6a97e29ec562ede874ec6cf6 https://doi.org/10.1186/s12929-026-01288-1

View Full Paper

Ask AI

Bookmark

September 2, 2026Journal of Biomedical ScienceOpen Access

DA-GIP reduces myocardial fibrosis and systolic dysfunction in heart failure rats via Akt-dependent nitric oxide signaling.

View Full Paper

Ask AI

Bookmark

Why the study?

How GIP receptor activation regulates cardiac fibrogenesis and modulates cardiac function in heart failure remained unclear.

Population

Human cardiac fibroblasts and rats with isoproterenol-induced heart failure

Comparison

DA-GIP administration vs untreated controls

Design

In vitro cellular and in vivo animal experimental study

Follow-up

24 h for fibroblasts and 2 weeks for rats

Key result

DA-GIP significantly reduced myocardial fibrosis, chamber dilatation, and systolic dysfunction in rats with experimental heart failure through Akt-dependent nitric oxide signaling.

Authors

TLTing‐Wei Lee TLTing-I Lee SHSatoshi Higa

Discussion

Member takes

Overview

Hypothesis-generating for GIP agonism in HF remodeling; human trials required before clinical consideration.

Key Points

To investigate whether activating the glucose-dependent insulinotropic polypeptide (GIP) receptor suppresses cardiac fibroblast activity and mitigates heart failure, and to elucidate the underlying signaling pathways.
Treated human cardiac fibroblasts with [D-Ala2]GIP (DA-GIP; 10, 100, or 300 nM) for 24 hours to analyze cell migration, collagen synthesis, and intracellular signaling pathways.
Administered DA-GIP (24 nM/kg twice daily for 2 weeks) to rats with isoproterenol-induced heart failure to assess cardiac remodeling, chamber dimensions, and systolic function using echocardiography and Masson's trichrome staining.
DA-GIP (300 nM) significantly decreased cardiac fibroblast migration and suppressed the expression of pro-collagen IA1, pro-collagen III, and TGF-β1 proteins.
DA-GIP enhanced Akt and eNOS activation to stimulate nitric oxide production; pharmacologic inhibition of Akt blocked eNOS activation, and L-NAME attenuated DA-GIP antifibrotic effects.
In heart failure rats, DA-GIP treatment reduced myocardial fibrosis, attenuated ventricular chamber dilatation, and improved systolic dysfunction.

Structured PICO

Population

15 male Wistar rats, including 10 with isoproterenol-induced heart failure, treated with DA-GIP or vehicle for 2 weeks, alongside in vitro human cardiac fibroblast experiments.

Intervention

[D-Ala 2 ]GIP (DA-GIP; 10, 100, or 300 nM for 24 h in cells; 24 nM/kg twice daily for 2 weeks in rats)

Comparator

Untreated (control) cells and heart failure rats without DA-GIP administration

Outcome

Fibroblast migration, collagen production, intracellular signaling, cardiac structure, function, and fibrosissurrogate

Main Result

p-value: p=<0.005

GIP receptor agonism suppresses cardiac fibroblast activity and improves cardiac remodeling and function in experimental heart failure via Akt-dependent NO signaling.

Limitations

The results were obtained from cellular and animal models, and their clinical applicability remains to be established.
Future studies should incorporate pressure-volume loop analysis to further clarify the effects of GIP receptor agonism on ventricular mechanics in heart failure.

Cite This Study

synapsesocial.com/papers/6a97e29ec562ede874ec6cf6 https://doi.org/10.1186/s12929-026-01288-1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark